The antiretroviral agent atazanavir is associated with mild asymptomatic hyperbilirubinemia.
We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone.
Symptoms and laboratory evidence of hemolysis resolved upon discontinuation of dapsone, enabling successful antiretroviral therapy.
Symptomatic hyperbilirubinemia due to hemolytic anemia is a potential adverse event when using the combination of atazanavir and dapsone in the treatment of patients with the human immunodeficiency virus.
2012-01-23
Eng.
Antimicrobial agents and chemotherapy
The University of Texas Medical Branch, Department of Internal Medicine—Division of Infectious Diseases, Galveston, Texas, USA.
Antimicrob Agents Chemother. 2012 Feb;56(2):1081-3
© Galenicom 1999-2013